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ABSTRACT Ethidium bromide, acridine orange, 4'-(9-
acridinylamino)methanesulfon-o-anisidide (o-AMSA), and m-
AMSA induce the rapid binding of RecA protein to double-
stranded (ds) DNA. The filaments formed appear to retain the
drug and are 12.8 nm in diameter with an 8.0-nm pitch. Two
classes of drugs have been distinguished: (i) those that bind to
RecA protein and induce assembly at low relative concentra-
tions (e.g., ethidium bromide) and (i) those that do not appear
to interact directly with RecA protein and must be present at
relatively high drug concentrations to stimulate assembly (e.g.,
m-AMSA). Ethidium bromide, acridine orange, and quin-
acrine inhibit RecA protein binding to single-stranded DNA.
Addition of ATP to the drug-induced filaments causes the
protein to rapidly dissociate from dsDNA, and protein binding
to dsDNA diminishes upon extended exposure to room light.
We suggest that the structure of the drug-induced maments
may be more typical of the complex that initiates RecA protein
assembly along DNA rather than the product of extensive
polymerization as induced by adenosine 5'-[y-thioltriphos-
phate.
RecA protein is a recombinational scaffolding protein that
catalyzes homologous recombination reactions in Esche-
richia coli. Unlike the synthetic reactions of replication and
transcription, strand exchange occurs within large filaments
composed of RecA protein assembled onto DNA (reviewed
in ref. 1). Thus, an understanding of the molecular details of
DNA strand exchange will require elucidation of the struc-
ture, physical properties, and biological functions of active
nucleoprotein filaments. Structural studies of the complexes
that RecA protein forms upon binding to DNA have focused
on the helical filament formed along double-stranded (ds)
DNA in the presence of the ATP analog adenosine 5'-
[y-thio]triphosphate (ATP[yS]). The right-handed filaments
formed are extremely stable, have a 9.5-nm pitch and 10-nm
diameter (2-7), and extend the dsDNA to 1.5 times its original
length (3). When binding occurs on negatively supertwisted
DNA, the DNA becomes progressively unwound as RecA
protein coverage increases, and at a rate equivalent to an
unwinding of 11.5°-13° per base pair of RecA protein-bound
DNA (4, 5). These average values do not necessarily define
the local structure ofdsDNA within the filaments (7). None-
theless, the analogy with DNA intercalated with ethidium
bromide was evident. Intercalation of ethidium bromide into
dsDNA unwinds duplex DNA by 260 per intercalated mole-
cule (8-11). As indicated by model building and x-ray dif-
fraction analyses (12-14), the flat chromophores can maxi-
mally occupy sites between every other base pair with
adjacent sites unoccupied (neighbor exclusion). Since an
intercalating chromophore extends duplex DNA by ap-
proximately the width of a base pair (3.4 A), saturation of
linear dsDNA by ethidium must cause a net unwinding of 13°
per base pair and a 1.5-fold linear extension. These helical
parameters are thus the same as the average extension and
unwinding of dsDNA in the RecA protein dsDNA filaments
formed with ATP[yS]. This parallel led us to investigate how
a number of simple DNA intercalators might promote or
inhibit RecA protein binding to DNA.
MATERIALS AND METHODS
Protein and DNA. RecA protein and M13mp7 ds and
single-stranded (ss) DNAs were purified as described (15,
16). M13mp7 dsDNA was cleaved with Pst I endonuclease
(Bethesda Research Laboratories).
Drugs. Ethidium bromide, acridine orange, doxorubicin,
quinacrine, naladixic acid, distamycin, and caffeine were
purchased from Sigma. Ethidium homodimer was purchased
from Molecular Probes; ['4C]ethidium bromide was pur-
chased from Amersham; and ATP['yS] was purchased from
Boehringer Mannheim. The aminoacridine derivatives, 4'-
(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)
and its ortho isomer (o-AMSA), were obtained as a gift from
Tao Hsieh (Duke University); [14C]m-AMSA was the gift of
Richard Cysyck (National Cancer Institute). Actinomycin D
was a gift from Ryszard Kole at this university.
RecA Protein Binding Assays. In the RecA protein-binding
assays, linear dsDNA (2 ,ug/ml or 3 ttM in nucleotide pairs)
was incubated with or without drug for 10 min at 370C in 20
mM Hepes, pH 7.3/30 mM NaCl/0.1 mM EDTA (HNE
buffer). RecA protein was then added to 80 ,ug/ml (2.1 ,tM)
and incubation continued. Reaction vessels were sequestered
from light unless otherwise specified. To examine the effects
of light, reaction vessels without foil were incubated at 370C
and exposed to fluorescent room light. ATP[yS] filaments
were formed by incubating identical concentrations of RecA
protein and DNA as described above with 0.6 mM ATP[yS]
and 2 mM MgCl2 in HNE buffer.
Electron Microscopy (EM). Unless otherwise indicated,
RecA protein-DNA complexes were prepared for EM by
removing aliquots from the incubation mixture, fixing the
samples with glutaraldehyde, and then mounting onto glow-
charged thin carbon films (17, 18). Rapid freezing and freeze-
drying were carried out by briefly adsorbing the samples
(unfixed) to a thin carbon film supported by a copper mesh
grid. Excess liquid was blotted away and the samples were
plunged into liquid ethane chilled with liquid nitrogen. The
frozen samples were transferred into a Wiltek-modified Balz-
ers 300 freeze-etch machine and freeze-dried for 2 hr at
-850C. Samples were then rotary shadowcast with tantalum
at -1700C and lo0 torr (1 torr = 133.3 Pa). Molecule length
measurements were carried out by projecting the EM nega-
Abbreviations: ds, double stranded; ss, single stranded; ATP[yS],
adenosine 5'-[y-thio]triphosphate; EM, electron microscopy;
AMSA, 4'-(9-acridinylamino)methanesulfonanisidide.
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tives onto a Summagraphics digitizer tablet coupled to an
IBM PC-AT computer programmed with software developed
in this laboratory.
RESULTS
Several Simple Intercalators Cause RecA Protein to Bind
Tightly to dsDNA. Filter binding (19) and EM studies (3) have
demonstrated that RecA protein will not bind to dsDNA in
low salt buffers lacking nucleotides. To illustrate this, RecA
protein (2.1 ,uM) was incubated in the dark with linear
M13mp7 dsDNA (3 AM nucleotide pairs) in HNE buffer at
370C for 30 min. DNA-protein complexes were fixed in 1%
glutaraldehyde and chromatographed over Sepharose 4B.
When the fractions containing DNA were examined by EM,
only protein-free DNA was observed (Fig. LA). However,
when 15 ,uM ethidium bromide was included in an otherwise
identical incubation, much of the dsDNA was enveloped in a
protein sheath (Fig. 1B). Under these conditions, acridine
orange, m-AMSA, and o-AMSA were also found to stimulate
extensive RecA protein assembly onto dsDNA. Drugs that
failed to or only marginally stimulated RecA protein assem-
bly onto dsDNA (over a range of 0.15 to 60 AM) included
quinacrine, doxorubicin, actinomycin D, nalidixic acid, dis-
tamycin, caffeine, and ethidium homodimer.
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Structure of the Drug-Induced Filaments. The length of the
RecA protein filaments formed on linear dsDNA in the
presence of intercalating drugs did not vary significantly for
the four drugs that stimulated protein binding. When pre-
pared by negative staining (Fig. 1E) or rapid freezing and
freeze-drying (Fig. 1C), unfixed filaments measured 1.45 ±
0.07 (ethidium bromide; n = 18), 1.40 ± 0.07 (acridine orange;
n = 17), 1.46 + 0.09 (o-AMSA; n = 21), and 1.44 ± 0.09
(m-AMSA; n = 12) times the length of protein-free DNA
(1.00). For all drugs, the filament diameter measured 12.8 ±
0.8 nm, and the helical pitch measured 8.0 ± 0.8 nm.
Filaments formed by incubating RecA protein with dsDNA in
the presence of ATP[yS] and magnesium (Fig. 1D) were
extended 1.5-fold but had a 10-nm diameter and 9- to 9.5-nm
pitch (n = 16), in agreement with previous studies (3, 4, 20).
When the NaCl concentration in the assembly buffer was
increased from 30 to 150 mM, no RecA protein assembly
occurred with any drug. The concentration ofNaCl inducing
at least 50% protein loss from preassembled filaments (in
HNE buffer) was determined by adding NaCl to various
concentrations for 2 min (at 37°C) prior to fixation. By this
protocol, filaments were found to be stable up to 250 mM
NaCl in ethidium bromide, 200 mM NaCl in acridine orange,
150 mM NaCl in o-AMSA, and 100 mM NaCl in m-AMSA.
In comparison, RecA protein dsDNA filaments formed in the
FIG. 1. Visualization of the
drug-induced assembly of RecA
protein onto duplex DNA. When
linear M13mp7 DNA was incu-
bated with RecA protein in 20mM
Hepes/30 mM NaCI/0.1 mM
EDTA for 10 min at 37°C, no pro-
tein binding was detected (A).
However, addition of 15 ,uM
ethidium bromide to the incuba-
tion buffer resulted in the forma-
tion of helical nucleoprotein fila-
ments (B) that extended the du-
plex DNA to -1.5 times its
original length. Preparation of the
ethidium-induced filaments for
EM without fixation by rapid
freezing and freeze-drying re-
vealed a compact right-handed
helical substructure (C). Fila-
ments formed in the presence of
ATP[yS] (D) prepared for EM as
in C revealed a more extended
helical pitch. Negative staining of
unfixed complexes of RecA pro-
tein and relaxed circular M13mp7
dsDNA induced by ethidium bro-
mide as in B with 2% aqueous
uranyl acetate (E) revealed a fila-
ment diameter of 12.8 nm and a
helical repeat of 8.0 nm. (A and B,
bar = 0.5 ,m; C and D, bar = 0.05
,m; E, bar = 0.2 ,um.)
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presence of ATP[yS] were stable to challenge by at least 700
mM NaCi. When the filaments were formed in the presence
of the drugs and then 1-5 mM ADP, ATP, or ATP[yS] (with
or without magnesium) was added for 2 min, no binding of
RecA protein to the dsDNA was observed by EM.
The drug-induced binding of RecA protein to supertwisted
M13mp7 DNA resulted in highly twisted and aggregated
complexes whose structure was difficult to interpret. This
was likely due to unwinding of the dsDNA from both drug
intercalation and the binding of RecA protein.
Drug-Induced RecA Protein dsDNA Filaments Form Rap-
idly. The kinetics ofRecA protein assembly onto dsDNA for
each drug was followed. The dsDNA (3 ,tM nucleotide pairs)
and drug (15 ,M) were incubated for 10 min at 370C, RecA
protein (2.1 AM) was added, and aliquots were withdrawn
over 60 min, fixed, and prepared for EM as described in Fig.
1. For each time point, low magnification fields containing
many molecules were photographed and the total amount of
protein-free and protein-covered DNA was determined. The
latter value was corrected for the 1.5-fold greater length ofthe
protein-covered regions. Nearly all of the dsDNA was cov-
ered by RecA protein within 5-10 min (Fig. 2A). Numerous
partially covered dsDNA molecules were found over the first
5 min and were characterized by multiple protein tracts. The
assembly kinetics for ethidium bromide, acridine orange, and
o-AMSA were similar: by 10 min, >90% of the dsDNA was
covered by RecA protein. This coverage was sustained over
the 60 min of incubation. While the early assembly kinetics
with m-AMSA were similar, protein coverage was found to
A
decline at later times. In contrast to the very rapid rate of
assembly induced by these drugs, the assembly induced by
ATP[yS] was much slower (Fig. 2A). Here, there were few
partially covered DNAs, and they contained only single
RecA protein tracts, indicating that assembly was nucleation
limited.
Dose-Response Curves Suggest Two Different Modes by
Which These Drugs Stimulate RecA Protein Binding. The
dependence ofRecA protein assembly on drug concentration
was followed by EM. Drug concentrations ranged from 0.5 to
60 mM, corresponding to 0.1-40 times the available interca-
lation sites in the reaction, assuming a maximum number of
intercalation sites based on neighbor-exclusion stoichiom-
etry. The drug and dsDNA were incubated for 10 min at 37°C,
RecA protein (2.1 ,uM) was added, and incubation continued
for 10 min. As shown in Fig. 2C, 0.15-1.5 ,M ethidium
bromide or acridine orange produced only low levels of
protein binding. However, at 3 ,M, >60% ofthe dsDNA was
fully covered by RecA protein. Increasing concentrations of
ethidium bromide (up to 60 ,M) produced high levels ofDNA
coverage, but concentrations of acridine orange >15 AfM
yielded lower levels of coverage. In contrast to ethidium
bromide and acridine orange, the AMSAs produced a more
gradual dose-dependent increase in protein coverage, with
o-AMSA being somewhat more efficient than m-AMSA at
intermediate drug concentrations (7.5-15 ,M; Fig. 2C).
In the experiments described in Fig. 2C, the greatest
incremental increase in RecA protein binding with ethidium
bromide and acridine orange occurred when the drug con-
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FIG. 2. The effects of intercalating agents on RecA protein binding to dsDNA. (A) Incubations were carried out as described in Fig. 1 (3
,uM dsDNA, 2.1 AM RecA protein, ± drug) and followed over 60 min with reactions sequestered from light. Samples were fixed and prepared
for EM as described in Fig. 1 A and B. The amount of RecA protein coverage of the DNA was determined directly from the micrographs.
Incubations included ethidium bromide (9), acridine orange (i), o-AMSA (*), m-AMSA (A), magnesium and ATP[vyS] (o), or buffer alone (o).
(B) Identical reactions were carried out in room light. (C) The concentration dependence of the drug-induced binding of RecA protein to duplex
DNA is shown. Linear M13mp7 dsDNA was incubated with various concentrations of drugs for 10 min at 37°C; RecA protein was then added
to 2.1 AM, and incubation continued for 10 min. Samples were fixed and prepared for EM as in A and B. Symbols are the same as described
above. (D) Inhibition of RecA protein binding to ssDNA by ethidium bromide is shown. In separate reactions, RecA protein (2.1 jM) was
incubated with ethidium bromide at the molar ratios indicated for 10 min prior to addition of either ssDNA (m; 3 ,uM bases) or dsDNA (e; 3
,uM base pairs). After 10 min of incubation, samples were fixed and spread from 40%o formamide (21). For all data points shown, the amount
of DNA coverage by RecA protein was determined by measurements taken directly from electron micrographs.
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centrations were raised from 1.5 to 3 ,uM. Since the assembly
reaction mixtures contained 2.1 ,uM RecA protein, this
suggested that drug-induced binding might be stimulated by
a direct interaction of ethidium bromide or acridine orange
with RecA protein, independent of the DNA concentration.
To examine this, 3 ,uM RecA protein was incubated with 3
AM drug for 10 min at 37TC, and then dsDNA was added to
30 ,M (in nucleotide pairs). This concentration of drug could
fill, at most, one-fifth of the available intercalation sites on
the linear dsDNA. Both ethidium bromide and acridine
orange efficiently stimulated RecA protein assembly, and it
appeared that nearly all of the RecA protein was bound to the
dsDNA, since inspection of the reaction mixtures by EM
after 10 min (without Sepharose 4B chromatography) re-
vealed little free protein. Little or no protein binding was seen
under these conditions with the AMSAs or any of the other
drugs tested. These observations suggested that DNA satu-
ration by the AMSAs was required before protein binding
could occur, but RecA protein may directly bind ethidium
bromide or acridine orange and then bind dsDNA to form a
ternary complex.
Somewhat lower levels of RecA protein binding were
observed in the 10-min assembly reactions containing the
AMSAs than seen previously (compare Fig. 2 A with C). We
cannot fully explain this discrepancy, although some loss of
solubility of the stock drug (dissolved in dimethyl sulfoxide)
over time or the relatively high sensitivity of m-AMSA-
induced RecA protein assembly to light (see Fig. 2B) may
have been contributing factors.
RecA Protein Binds Ethidium Bromide in Solution. Direct
drug-protein interactions were examined by incubating RecA
protein (13 gM) with either [14C]ethidium bromide or m-
AMSA (13 ,M) for 10 min at 37°C and applying the sample
(unfixed) to Sepharose 4B columns equilibrated with buffer
containing 13 ,uM labeled drug according to the method of
Hummel and Dreyer (22). Fractions were collected and the
amount of protein-associated 14C label was determined by
liquid scintillation counting. The emergence of RecA protein
was accompanied by an increase in 14C above background
(Fig. 3) that corresponded to a stoichiometry of 1 ethidium
molecule per 1.6-3 RecA protein monomers (separate ex-
periments). The protein-associated peak of label was not
observed when [14C]m-AMSA was used or when labeled
ethidium was incubated with other proteins, such as protein-
ase K. The addition of 2 mM ATP[yS] to a mixture of RecA
protein and [14C]ethidium bromide 2 min prior to loading onto
the column abolished the protein-associated ethidium label.
Some Drugs Inhibit the Binding of RecA Protein to ssDNA.
In simple, low-salt buffers, RecA protein readily binds to
ssDNA (3). To determine the effects of intercalating agents
on this interaction, RecA protein (2.1 uM) was incubated
with each drug tested (2.1-40 AM) for 10 min at 37°C and then
ssDNA or dsDNA was added (3 ,M bases or base pairs).
After 10 min further incubation, the samples were fixed with
1% glutaraldehyde and then prepared for EM by surface
spreading from 40% formamide (21). This EM preparative
method was required to spread out protein-free ssDNA. The
fractional coverage of ssDNA and dsDNA was then mea-
sured. A 5-fold molar excess of ethidium bromide, acridine
orange, quinacrine, or doxorubicin (relative to protein mono-
mers) inhibited RecA protein binding to ssDNA by at least
50% and assembly was completely blocked when a 10-fold
molar excess was used (Fig. 2D). In contrast, a 10-fold molar
excess of m-AMSA or o-AMSA did not inhibit RecA protein
assembly onto ssDNA.
Drug-Induced RecA Protein-DNA Filaments Are Light Sen-
sitive. Intercalating agents contain chromophores that can
absorb visible light and damage proteins through the gener-
ation of reactive oxygen (23). When the kinetics of RecA

















FIG. 3. Analysis of the binding of ethidium bromide and m-
AMSA to RecA protein. Following the procedure of Hummel and
Dreyer (22), RecA protein (13 AM) was incubated with either
[14C]ethidium bromide (13 ,uM) or [14C]m-AMSA (13 AM) for 10 min
in HNE buffer and applied to 2-ml Sepharose 4B columns equili-
brated with HNE buffer containing 13 ,uM labeled drug. A peak of
ethidium bromide emerged with the RecA protein that corresponded
to a stoichiometry of 1 ethidium molecule per 1.6 molecules of RecA
protein (A). A protein-associated drug peak was not found when
labeled m-AMSA was used (B) or when labeled ethidium bromide
was incubated with 13 ,M proteinase K (D). In addition, the
protein-associated [14C]ethidium bromide peak could be abolished
by adding 2mM ATP[yS] to the reaction mixture just prior to loading
the sample onto the column (C). In A, the RecA protein profile of the
column fractions as determined by the Bio-Rad protein assay is
shown (o).
2A with the reactions exposed to fluorescent room light, a
time-dependent loss of RecA protein binding was observed
(Fig. 2B). Light inactivation was not reversible, since incu-
bation of the dsDNA and RecA protein with 15 gM ethidium
bromide for 60 min (as in Fig. 2A) followed by further
incubation for 60 min in the dark did not restimulate binding.
The involvement of free radicals in this process was indicated
by the finding that inclusion of 1 mM ascorbic acid inhibited
the light-dependent protein loss by -50% (data not shown).
DISCUSSION
In this paper, we report that ethidium bromide, acridine
orange, o-AMSA, and m-AMSA induce the rapid binding of
RecA protein to dsDNA. This binding produces helical
filaments that are similar to, but measurably different from,
any RecA protein dsDNA filaments previously described.
Two classes of drugs can be distinguished: ethidium bromide
(and likely acridine orange) bind to RecA protein in the
absence of DNA, while m-AMSA (and presumably o-AMSA)
do not. The drug-induced filaments are rapidly dissociated by
the addition of ATP, and filament formation is sensitive to
room light. Finally, ethidium bromide and acridine orange,
but not the AMSAs, inhibit RecA protein binding to ssDNA.
These studies used a quantitative EM assay to measure the
coverage ofDNA by RecA protein. While the assay involved
Biochemistry: Thresher and Griffith
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chemical fixation and gel-exclusion chromatography, sam-
ples were routinely imaged without fixation or filtration by
negative staining, and in no cases were significant differences
observed.
Evidence that the drug-induced filaments retain the drugs
within them stems primarily from experiments (data not
shown) in which RecA protein dsDNA filaments were formed
by using labeled ethidium bromide or m-AMSA. It was found
that labeled drug was retained in the unfixed filaments after
chromatography over Sepharose 4B. For both drugs, we
estimated that 1 drug molecule remained bound per 6-9 base
pairs in the DNA-protein complexes, arguing against a strict
exclusion of the drug from the filaments. The lack of a
drug-associated peak with [14C]m-AMSA by Hummel-
Dreyer analysis could have been indicative of a very tight
association between the drug and RecA protein. Without
exchange, no peak would be seen. This is unlikely, however,
since the association between ethidium bromide and RecA
protein correlated well with protein binding, yet high con-
centrations of the AMSAs were required to stimulate RecA
protein assembly. In addition, the inhibition ofRecA protein
binding to ssDNA by ethidium bromide, acridine orange, and
quinacrine, but not by the AMSAs, may reflect the differ-
ences between drugs in their affinities for RecA protein.
Of the drugs that promoted RecA protein assembly, only
acridine orange showed a reduced level of protein assembly
as the drug concentration increased. A trivial explanation is
that this drug was supplied as a zinc salt and that the metal
may have interfered with the protein DNA-drug interaction.
A more interesting analogy exists with dsDNA and topo-
isomerase II activity as stimulated by intercalating agents,
where the formation of a cleavable complex is observed to
peak and then decline as the drug concentration is increased
(24).
The sensitivity of the drug-induced filaments to room light
raises an important concern. The AMSAs and other interca-
lators are used extensively to interrupt the cycle of cleavage
and religation of dsDNA by topoisomerase II (25). We have
found that these drugs show dramatic differences in the
extent and longevity of RecA protein binding that is depen-
dent on the presence or absence of light. Clearly, the effects
of light on drug inactivation of topoisomerase II should be
determined.
The drug binding site on RecA protein has not been
defined. Our data can be interpreted as being consistent with
binding at or near the ATP binding site, the ssDNA binding
site, or possibly another site(s). The observations that drug-
induced filaments were rapidly disrupted by nucleotides and
that ATP[yS] released ethidium bromide from RecA protein
in the absence ofDNA argue that the drugs compete for the
ATP binding site on RecA protein. However, ATP binding
could induce a conformational change in RecA protein that
facilitates the release of the drug molecule bound to RecA
protein at some other site, such as the ssDNA binding site,
as suggested by the inhibition of RecA protein binding to
ssDNA exhibited by several drugs.
We know little about the structure ofthe dsDNA within the
drug-induced filaments. Models describing the nature of
DNA near sites of actinomycin D intercalation (26) may
provide insights, but in our studies this drug did not induce
RecA protein binding. Before a model of the DNA within the
drug-induced filaments can be presented, it will be essential
to determine the exact number of drug molecules bound per
base pair, whether the drug is bound to the DNA or to the
protein, and, if bound to the protein, whether it is near the
ATP binding site.
The binding of RecA protein to ss- and dsDNA occurs in
two steps: nucleation followed by polymerization. RecA
protein will nucleate on ssDNA with relative ease; this can be
enhanced by high levels of ATP and depressed by excess
amounts of SSB protein (18). Polymerization then proceeds
5' to 3' (27) to produce the active filaments that catalyze
strand exchange and enhance the cleavage of the repressors
of the SOS response. On dsDNA, nucleation is rare, but it can
be promoted by discontinuities in the helix such as thymine
dimers (28), psoralen crosslinks (29), B-Z junctions (30), and
extra base bulges (C. Bortner, Y.-W. Wang, and J.D.G.,
unpublished observations). Thus, understanding the nature
of the nucleation step and structure of the DNA-protein
complexes that initiate the assembly of RecA protein fila-
ments is central to defining the biological roles ofthis protein.
Here, we have shown that intercalating drugs are highly
efficient at inducing RecA protein binding. Our presumption
is that they do so by creating nucleation sites. Since the
number of drug molecules per DNA length is high, these
filaments may be thought of as a continuous nucleation
complex. In contrast, the ATP[yS]-induced filaments repre-
sent the product of extensive polymerization. If this model is
true, it could explain the structural differences seen between
drug-induced and ATP[yS]-induced filaments. It also sug-
gests that the drug-induced filaments should provide a valu-
able tool for probing the early events in which RecA protein
binds to DNA.
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